Fatemeh Malekinejad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fatemeh Malekinejad has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Mehrdad Nourizadeh
Neurosciences Research Center Tabriz University of Medical Sciences Tabriz Iran
3 shared publications - Amirreza Naseri
Student Research Committee Tabriz University of Medical Sciences Tabriz Iran
2 shared publications - Mahnaz Talebi
Neurosciences Research Center (NSRC) Tabriz University of Medical Sciences Tabriz Iran
2 shared publications - Shahrzad Fakhkhari
Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications - Sina Hamzehzadeh
Student Research Committee Tabriz University of Medical Sciences Tabriz Iran
2 shared publications - Alireza Aghili
Department of Orthopedics, School of Medicine, Tabriz University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- Open Access
- 28 October 2026
- Published by Springer Nature in Discover Oncology
Programmed death ligand 1 and the tumor microenvironment shape immune checkpoint combination therapy in triple-negative breast cancer
- 28 October 2026
- Published by Springer Nature in Discover Oncology
Open AccessProgrammed death ligand 1 and the tumor microenvironment shape immune checkpoint combination therapy in triple-negative breast cancer
- Open Access
- 22 September 2026
- Published by Springer Nature in European Journal of Medical Research
The gut microbiome in autoimmune disease: mechanisms, interactions, and therapeutic potential
- 22 September 2026
- Published by Springer Nature in European Journal of Medical Research
Open AccessThe gut microbiome in autoimmune disease: mechanisms, interactions, and therapeutic potential
- Open Access
- 10 August 2026
- Published by Wiley in Veterinary Medicine and Science
- Vol. 12 (5)
Artificial Intelligence in Veterinary Neurology: Comparative Insights From Human Medicine and Cross‐Species Technology Transfer
Background: Artificial intelligence (AI) is increasingly explored in veterinary neurology for pattern recognition, prediction and clinical decision support, with relevance to comparative and translational neuroscience. Objectives: This review examines AI applications in veterinary neurology, compares them with human neurology and evaluates cross‐species technology transfer within a One Health framework. Methods: A narrative review synthesized evidence across AI domains in veterinary neurology, including neuroimaging and radiomics, electrophysiology and seizure detection or forecasting, gait and pain assessment, morphometric biomarker discovery, prognostic modelling and laboratory diagnostic tools. Human studies were considered to identify translational opportunities, methodological challenges and the value of transfer learning and domain adaptation. Results: Available evidence suggests that AI holds promise for pattern recognition, prediction and decision support in veterinary neurology. Reported applications include canine brain tumour classification, spinal lesion grading, seizure monitoring and quantitative gait analysis, with encouraging performance. However, most applications remain proof‐of‐concept. The evidence base is dominated by retrospective single‐centre studies with small samples, heterogeneous protocols and limited prospective or external validation. Model calibration, uncertainty reporting and clinically relevant error trade‐offs are often insufficiently addressed. Transfer learning and domain adaptation may help overcome limited veterinary datasets, while naturally occurring neurological disease in dogs may also support refinement of human AI systems. Conclusions: AI in veterinary neurology is a promising but early field. Future progress will require multi‐centre collaboration, standardized data practices, explainable and ethically governed models and stronger One Health partnerships to support safe translation.
- 10 August 2026
- Published by Wiley in Veterinary Medicine and Science
- Vol. 12 (5)
Open AccessArtificial Intelligence in Veterinary Neurology: Comparative Insights From Human Medicine and Cross‐Species Technology Transfer
Background: Artificial intelligence (AI) is increasingly explored in veterinary neurology for pattern recognition, prediction and clinical decision support, with relevance to comparative and translational neuroscience. Objectives: This review examines AI applications in veterinary neurology, compares them with human neurology and evaluates cross‐species technology transfer within a One Health framework. Methods: A narrative review synthesized evidence across AI domains in veterinary neurology, including neuroimaging and radiomics, electrophysiology and seizure detection or forecasting, gait and pain assessment, morphometric biomarker discovery, prognostic modelling and laboratory diagnostic tools. Human studies were considered to identify translational opportunities, methodological challenges and the value of transfer learning and domain adaptation. Results: Available evidence suggests that AI holds promise for pattern recognition, prediction and decision support in veterinary neurology. Reported applications include canine brain tumour classification, spinal lesion grading, seizure monitoring and quantitative gait analysis, with encouraging performance. However, most applications remain proof‐of‐concept. The evidence base is dominated by retrospective single‐centre studies with small samples, heterogeneous protocols and limited prospective or external validation. Model calibration, uncertainty reporting and clinically relevant error trade‐offs are often insufficiently addressed. Transfer learning and domain adaptation may help overcome limited veterinary datasets, while naturally occurring neurological disease in dogs may also support refinement of human AI systems. Conclusions: AI in veterinary neurology is a promising but early field. Future progress will require multi‐centre collaboration, standardized data practices, explainable and ethically governed models and stronger One Health partnerships to support safe translation.
- Open Access
- 6 January 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Polymorphisms in CLOCK and ARNTL/BMAL-1 genes in multiple sclerosis: a systematic review and meta-analysis
Multiple sclerosis (MS) is still under investigation for its pathogenesis. This study explores the relationship between the key circadian rhythm regulators
- 6 January 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Open AccessPolymorphisms in CLOCK and ARNTL/BMAL-1 genes in multiple sclerosis: a systematic review and meta-analysis
Multiple sclerosis (MS) is still under investigation for its pathogenesis. This study explores the relationship between the key circadian rhythm regulators
- Open Access
- 1 January 2026
- Published by Wiley in Parkinson's Disease
- Vol. 2026 (1)
Air Pollution and Parkinson’s Disease Pathology: Clinical Evidence and the Molecular Mechanisms Linking Airborne Toxicants to Neuroinflammation and Neurodegeneration
Parkinson’s disease (PD) is a neurodegenerative condition, and its rising prevalence necessitates the urgent need to identify modifiable risk factors. Air pollution, a pervasive and also escalating public health problem, has emerged as a potential contributor to the incidence and progression of PD. As urbanization and industrialization continue to exacerbate global air pollution levels, understanding the relationship between airborne toxicants and PD is a pressing scientific and public health priority. In this review, we critically discuss the current epidemiological evidence and the cellular and molecular mechanisms underlying air pollution‐induced neurodegeneration in PD. Clinical studies associate long‐term interaction with pollutants such as nitrogen oxides, particulate matter, and ozone with increased PD risk. Evidence also suggests that air pollution worsens PD prognosis. Mechanistically, air pollution is hypothesized to contribute to PD pathogenesis through gut microbiome alternations, oxidative stress, and neuroinflammatory pathways, as well as promoting α‐synuclein aggregation.
- 1 January 2026
- Published by Wiley in Parkinson's Disease
- Vol. 2026 (1)
Open AccessAir Pollution and Parkinson’s Disease Pathology: Clinical Evidence and the Molecular Mechanisms Linking Airborne Toxicants to Neuroinflammation and Neurodegeneration
Parkinson’s disease (PD) is a neurodegenerative condition, and its rising prevalence necessitates the urgent need to identify modifiable risk factors. Air pollution, a pervasive and also escalating public health problem, has emerged as a potential contributor to the incidence and progression of PD. As urbanization and industrialization continue to exacerbate global air pollution levels, understanding the relationship between airborne toxicants and PD is a pressing scientific and public health priority. In this review, we critically discuss the current epidemiological evidence and the cellular and molecular mechanisms underlying air pollution‐induced neurodegeneration in PD. Clinical studies associate long‐term interaction with pollutants such as nitrogen oxides, particulate matter, and ozone with increased PD risk. Evidence also suggests that air pollution worsens PD prognosis. Mechanistically, air pollution is hypothesized to contribute to PD pathogenesis through gut microbiome alternations, oxidative stress, and neuroinflammatory pathways, as well as promoting α‐synuclein aggregation.